Group 1 - The article discusses several mergers and acquisitions involving various companies in the pharmaceutical and investment sectors, with specific focus on the completion dates of these transactions [2][3] - The first case involves E Fund Management Co., Ltd. and Zhuhai Runhe Zhihui Pharmaceutical Investment Co., Ltd., with a new establishment case set for February 9, 2026 [2] - Guangzhou Pharmaceutical Holdings Limited is acquiring equity in Zhejiang Pharmaceutical Industry Co., Ltd., with the deal expected to close on February 11, 2026 [2] - The acquisition case involving Guotou Transportation Holdings Co., Ltd. and Hainan Yangpu Development and Construction Holdings Co., Ltd. is also scheduled for completion on February 11, 2026 [2] - Guangzhou Industrial Investment Holdings Group Co., Ltd. is set to acquire equity in Ningbo Xusheng Group Co., Ltd., with the transaction expected to finalize on February 13, 2026 [2]

Core Viewpoint - Zhejiang Medicine (600216.SH) has signed a partnership agreement to invest in the Langfang Xinhui Silver Economy Equity Investment Fund, committing a total of 250 million yuan, which represents 31.25% of the fund's total capital of 800 million yuan [1] Group 1: Investment Details - The partnership agreement was signed on February 24, 2026, with CITIC Medical Health Equity Investment Private Fund Management (Beijing) Co., Ltd. as the general partner [1] - The fund aims to focus on investments in the silver economy and the healthcare sector, targeting companies that can rapidly increase in value [1] - The fund's objective is to maximize returns for all partners through reasonable commercial efforts and to achieve a win-win outcome [1]

Core Viewpoint - Zhejiang Medicine (600216.SH) has signed a partnership agreement to invest in a fund focused on the silver economy and healthcare sector, committing 250 million yuan, which represents 31.25% of the total fund size of 800 million yuan [1] Group 1: Investment Details - The partnership agreement was signed on February 24, 2026, with CITIC Medical Health Equity Investment Private Fund Management (Beijing) Co., Ltd. as the general partner [1] - The total subscribed capital of the partnership enterprise is 800 million yuan, with Zhejiang Medicine contributing 250 million yuan [1] - The fund aims to invest in companies within the silver economy and healthcare sectors, enhancing the value of the invested enterprises [1] Group 2: Fund Management and Objectives - CITIC Medical Health Equity Investment Private Fund Management (Beijing) Co., Ltd. will act as the general partner, executive partner, and fund manager [1] - The fund's objective is to maximize returns for all partners through reasonable commercial efforts and to achieve a win-win outcome [1]

Group 1 - The core viewpoint of the article is that 康龙化成 (300759.SZ) is increasing its investment in 宁波甬康 by 50 million RMB to enhance its investment capabilities and promote high-quality development in the pharmaceutical industry [1] - After this additional investment, the total contribution of the company to 宁波甬康 will amount to 150 million RMB, representing 87.1343% of the total subscribed capital of the fund [1] - The company signed a limited partnership agreement regarding 宁波甬康 on January 9, 2026 [1]

Overview - The company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has participated in the establishment of a private equity investment fund named "China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership)" [2] Group 1 - On October 28, 2025, the company signed a partnership agreement with 11 other investors to jointly establish the fund [2] - The fund has completed its registration with the Asset Management Association of China [3] - The fund is managed by Shenzhen China Resources Capital Equity Investment Co., Ltd. and is custodied by China Merchants Bank Co., Ltd. [3]

Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference will be held on October 26-27, 2025, in Nanjing, focusing on global pharmaceutical frontiers and capital trends, gathering top minds in the pharmaceutical innovation and investment fields [1][2]. Conference Information - The conference will take place at Fengda International Hotel, Nanjing, and will cover multiple thematic forums including innovative drug research and development, clinical research, cell and gene therapy, investment mergers and acquisitions, capital markets, and commercial insurance policies [2]. - The agenda includes various sub-forums such as cell and gene therapy, weight loss innovation, clinical data, anti-tumor new drugs, and international roadshows, ensuring comprehensive coverage of the pharmaceutical industry [3][4]. Key Topics - The conference will address core challenges and development trends in the pharmaceutical industry, emphasizing internationalization, investment financing, and regulatory policies, with a focus on the synergy between basic medical insurance and commercial health insurance [5]. - Discussions will include the strategies of Chinese innovative pharmaceutical companies in global markets, particularly in terms of licensing, mergers, and new investment trends [5][6]. Expert Participation - The conference will feature senior experts, clinical specialists, industry leaders, and frontline investors who will share insights on breakthrough technologies, practical experiences in investment mergers, and policy interpretations [4][6]. - Notable speakers include leaders from prestigious institutions and companies, contributing to discussions on the construction of innovative ecosystems and cross-sector collaboration [4][6]. Forum Structure - The conference will be structured around multi-dimensional forums designed to promote deep dialogue and knowledge sharing across clinical, industrial, capital, and policy fields, with three core discussion directions: global strategic layout, capital collaborative innovation, and market trend outlook [6].

Group 1 - The company announced the establishment of a new partnership for investment in the pharmaceutical industry, involving its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. [1] - The total committed capital for the new partnership, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), is set at 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total commitment [1]

Core Viewpoint - East China Pharmaceutical (000963.SZ) aims to enhance its industrial investment ecosystem and expand its industry chain layout by establishing a partnership with Shanghai Fuguang Private Fund Management Co., Ltd. and other investors to create a specialized pharmaceutical industry investment fund totaling RMB 2 billion [1] Group 1: Investment Details - The total committed capital for the specialized pharmaceutical industry investment fund is RMB 2 billion, with East China Pharmaceutical contributing RMB 980 million, representing a 49% stake [1] - The fund will focus on investment areas including innovative drugs, medical aesthetics, health and wellness, animal health, and sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]